Previous Close | 2.1100 |
Open | 2.1100 |
Bid | 2.1100 x 1800 |
Ask | 2.1500 x 4000 |
Day's Range | 2.0900 - 2.1500 |
52 Week Range | 1.9500 - 3.8400 |
Volume | |
Avg. Volume | 4,852,855 |
Market Cap | 1.141B |
Beta (5Y Monthly) | 0.83 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3600 |
Earnings Date | Nov 01, 2023 - Nov 06, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.83 |
FOSTER CITY, Calif., September 29, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for imetelstat, a first-in-class investigational telomerase inhibitor, for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS). The MAA was submitted earlier this month and is now under regulatory review b
Here is your Pro Recap of the biggest analyst picks you may have missed since Friday: upgrades at CVS Health, Brown Forman, Geron, and a buy initiation for Block. Wolfe Research upped CVS Health (NYSE: NYSE:CVS) to Outperform from Peerperform with a price target of $80.00, prompting the shares to shoot higher after word of the upgrade hit the wires intraday Monday.
FOSTER CITY, Calif., September 11, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer (CFO) and Treasurer, effective September 25, 2023. Ms. Robertson's appointment follows the retirement of Olivia Bloom, Geron's incumbent CFO, also effective September 25, 2023. Ms. Bloom's retirement brings to a close a remarkable career of nearly 30 years on Geron’s f